CRSP

CRISPR THERAPEUTICS AG

CRSP · CIK 1674416 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$4M
20182025
Net Income−$582M
20182025
Operating CF−$345M
20182025
Free Cash Flow−$346M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.0B$0.0B$0.4B$0.0B$0.9B$0.0B$0.1B$0.0B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.3B$0.3B$0.4B$0.5B$0.4B$0.3B$0.2B$0.1B
SG&A Expense————————
Operating Income$-0.7B$-0.5B$-0.2B$-0.7B$0.4B$-0.1B$0.0B$-0.0B
Net Income$-0.6B$-0.4B$-0.2B$-0.7B$0.4B$-0.1B$0.0B$-0.0B
EPS (Basic)$-6.47$-4.34$-1.94$-8.36$4.97$-1.50$0.53$-0.92
EPS (Diluted)$-6.47$-4.34$-1.94$-8.36$4.70$-1.50$0.51$-0.92

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$2.3B$2.2B$2.2B$2.2B$2.8B$1.8B$1.1B$0.5B
Current Assets$2.0B$1.9B$1.9B$1.9B$2.4B$1.7B$1.0B$0.5B
Cash & Equivalents$0.3B$0.3B$0.4B$0.2B$0.9B$1.2B$0.9B$0.5B
Total Liabilities$0.3B$0.3B$0.3B$0.4B$0.4B$0.2B$0.1B$0.1B
Current Liabilities$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B
Stockholders' Equity$1.9B$1.9B$1.9B$1.9B$2.4B$1.7B$0.9B$0.4B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.3B$-0.1B$-0.3B$-0.5B$0.5B$-0.2B$0.1B$-0.1B
Investing Cash Flow$-0.0B$-0.3B$0.4B$-0.3B$-1.0B$-0.5B$0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.1B$0.0B$0.0B$0.0B
Financing Cash Flow$0.4B$0.3B$0.1B$0.0B$0.3B$1.0B$0.4B$0.3B
← Companies